Anti-TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) Monoclonal Antibody (Clone: TIGIT/3017)

TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4+ T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation) . It has been demonstrated to be upregulated on T cells in many cancers and is an immuno-oncology target for therapy.